CLINICAL TRIALS PROFILE FOR VICTRELIS

All Clinical Trials for VICTRELIS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00959699 ↗	A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2009-11-01	The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC) plus weight-based dosing (WBD) of ribavirin (RBV) (600 mg/day to 1400 mg/day) PO to therapy with PegIFN-2b + RBV alone in adult participants coinfected with human immunodeficiency virus (HIV) and previously untreated chronic hepatitis C virus (HCV) genotype 1. Boceprevir is a potent, orally administered, novel serine protease inhibitor, specifically designed to inhibit the HCV nonstructural protein 3 (NS3) protease and, thereby, inhibit viral replication in HCV-infected host cells. The mechanism of inhibition represents a new mechanism of action compared to both interferon alfa and ribavirin. Based on previous experience with PegIFN-2b and RBV in combination with boceprevir in the HCV-monoinfected population, this combination treatment is expected to provide significant benefit to the HIV/HCV coinfected population. Given the high unmet medical need of these participants and the benefit of the addition of boceprevir to PegIFN-2b/RBV, it is important to demonstrate the safety and efficacy of boceprevir in combination with PegIFN-2b/RBV in participants coinfected with HIV/HCV. This is a randomized, multi-center trial, double-blinded for boceprevir or placebo in combination with open-label PegIFN-2b/RBV in participants coinfected with HIV and previously untreated chronic HCV (genotype 1), to be conducted in conformance with Good Clinical Practice (GCP). This trial consists of two arms, one control arm (Arm 1) and one experimental arm (Arm 2). Participants in the control arm (Arm 1) may receive boceprevir/PegIFN-2b/RBV via a crossover arm.
NCT01353911 ↗	Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2011-06-27	This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered in combination with peginterferon alfa-2b (Peg-IFN) and ribavirin (RBV) in treatment-naïve (TN) participants with chronic hepatitis C.
NCT01390844 ↗	Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2011-10-21	This study will assess the efficacy of boceprevir (BOC) in combination with PegIntron (pegylated interferon alfa-2b) (PEG) and ribavirin (RBV) in response guided therapy compared to the efficacy of standard-of-care therapy alone in adult subjects with chronic hepatitis C (CHC) genotype 1 who failed prior treatment with pegylated interferon and RBV in the Asia Pacific population. The primary hypothesis is that the proportion of participants achieving sustained virologic response in the experimental therapy regimen (BOC/PEG+RBV) is superior to that in the control arm (Placebo/PEG+RBV), in the Full Analysis Set (FAS) population.
NCT01465516 ↗	Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir	Terminated	Arrowhead Regional Medical Center		2011-11-01	Hypothesis Response guided therapy improves significantly the overall SVR in Hispanics compared to historical control. There is no difference in SVR between patients with an undetectable HCV RNA at week 8 and week 28 who received a 4 week lead-in of PR plus 24 weeks of PR+BOC based treatment and patients with detectable HCV RNA at week 8 and undetectable HCV RNA at week 24 who received a lead-in of PR plus 32 weeks PR+BOC followed by based therapy and 12 weeks of PR.
NCT01471717 ↗	Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects	Completed	Bristol-Myers Squibb	Phase 1/Phase 2	2011-10-01	This study is designed to evaluate the potential for a pharmacokinetic drug-drug interaction between INX-08189 and Victrelis, a Direct Acting Antiviral (DAA).
NCT01912495 ↗	Dutch Acute HCV in HIV Study (DAHHS)	Completed	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Phase 2	2013-08-01	Prospective open label proof of concept feasibility interventional clinical trial in which 60 acute HCV genotype 1 patients co-infected with HIV will receive 12 weeks of boceprevir in addition to Standard Of Care Peginterferon + Ribavirin if they show a Rapid Viral Responds at week 4. The primary hypothesis of this study is that the subset of patients with a Rapid Viral Responds after 4 weeks of triple therapy with boceprevir, peginterferon alpha-2b (P) and ribavirin (RVR4) can be successfully treated with a shorter 12-week triple therapy regimen.

Clinical Trial Conditions for VICTRELIS

Condition Name

Condition Name for VICTRELIS
Intervention	Trials
Hepatitis C, Chronic	4
Hepatitis C	2
Hepatitis C Infection	2
HIV Infections	1

Condition MeSH

Condition MeSH for VICTRELIS
Intervention	Trials
Hepatitis C	8
Hepatitis	7
Hepatitis A	6
Hepatitis C, Chronic	4

Clinical Trial Locations for VICTRELIS

Trials by Country

Trials by Country for VICTRELIS
Location	Trials
United States	3
Netherlands	2
Hungary	1

Trials by US State

Trials by US State for VICTRELIS
Location	Trials
Ohio	1
Minnesota	1
California	1

Clinical Trial Progress for VICTRELIS

Clinical Trial Phase

Clinical Trial Phase for VICTRELIS
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	3
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for VICTRELIS
Clinical Trial Phase	Trials
Completed	6
Terminated	2
Withdrawn	1

Clinical Trial Sponsors for VICTRELIS

Sponsor Name

Sponsor Name for VICTRELIS
Sponsor	Trials
Merck Sharp & Dohme Corp.	4
Slotervaart Hospital	1
UMC Utrecht	1

Sponsor Type

Sponsor Type for VICTRELIS
Sponsor	Trials
Other	11
Industry	6
U.S. Fed	1

Last updated: July 27, 2026

VICTRELIS (boceprevir) clinical trials update, market analysis, and patent/entry risk projection

Executive summary: VICTRELIS (boceprevir) is an older, withdrawn-era direct-acting antiviral (DAA) for hepatitis C virus (HCV). Boceprevir’s clinical development and market footprint have been overtaken by newer, better-tolerated, pangenotypic regimens and interferon-free combinations. As a result, current market activity is limited to legacy use, inventory clearing, and residual payer/medical-policy effects rather than new trial-driven expansion. Commercial upside from continued adoption is low, and competitive pressure from newer DAAs drives de facto exit from mainstream formularies.

What is VICTRELIS (boceprevir) used for and what is its current clinical trial landscape?

Quick answer: Boceprevir was used in combination with peginterferon alfa and ribavirin for chronic HCV, primarily genotype 1, in specific treatment settings. Its late-stage clinical program focused on SVR12 outcomes, viral kinetics, and response-guided therapy. Newer regimens have displaced boceprevir, and the clinical trial ecosystem is no longer centered on boceprevir initiation.

Which HCV populations were targeted in the boceprevir trials?

Boceprevir trials largely stratified by:

• Treatment history (treatment-naïve vs prior null responders/relapsers/partial responders)
• Fibrosis stage and cirrhosis status
• Baseline viral load
• Prior genotype distribution, with genotype 1 predominating

What endpoints drove boceprevir’s development?

• SVR12 (sustained virologic response at 12 weeks post-treatment)
• Rapid virologic response and early viral kinetics
• Treatment duration reduction strategies using response-guided regimens

What is the practical status of boceprevir clinical development today?

Boceprevir is not the basis of current front-line HCV clinical programs. The active trial focus in HCV is dominated by modern DAAs and pangenotypic regimens, with boceprevir absent from the standard pipeline.

How do the key boceprevir phase 3 trials compare on efficacy, safety, and response-guided therapy?

Quick answer: The boceprevir pivotal evidence centered on higher SVR rates versus peginterferon/ribavirin alone, with an adverse-event profile dominated by cytopenias and interferon-associated tolerability issues, and with response-guided treatment duration as a key design element.

What was the efficacy profile vs control?

Across pivotal studies, boceprevir plus peginterferon alfa and ribavirin increased SVR12 rates relative to peginterferon alfa and ribavirin alone, with the magnitude varying by:

• Prior treatment status
• Baseline viral load
• Achieved on-treatment viral milestones used for response-guided approaches

How did safety outcomes shape adoption?

The safety profile limited uptake in real-world practice because:

• Peginterferon/ribavirin already carry tolerability burdens
• Boceprevir added additional risk, particularly anemia and other cytopenias
• Monitoring and dose adjustment demands increased burden on patients and clinicians

What market dynamics affect boceprevir demand and how has adoption changed vs newer HCV regimens?

Quick answer: Boceprevir’s market demand has structurally declined as interferon-free and pangenotypic regimens replaced interferon-based therapy. Remaining use is mostly residual and pathway-dependent, not growth-oriented.

Why has the market moved away from boceprevir?

Key drivers:

• Interferon-free standard of care replaced interferon-based regimens
• Newer DAAs improved tolerability and shortened treatment duration
• Pangenotypic options reduced genotype testing friction
• Higher regimen convenience reduced payer and provider friction

What are the commercial implications for boceprevir pricing and volume?

• Volume contraction is driven by guideline and formulary displacement
• Pricing power is weak in a declining category
• Bulk inventory clearing and limited continued reimbursement are the main near-term revenue mechanics

What is the revenue and market projection for VICTRELIS over the next 3–5 years?

Quick answer: Boceprevir’s forward commercial trajectory is flat-to-declining, with net exposure driven by legacy supply/distribution, residual patient starts, and contract tail effects. Growth projection is not credible under current HCV treatment standards.

Projection framework used for boceprevir

A realistic forecast for VICTRELIS must reflect:

• Guideline-led displacement by modern DAAs
• Reduced new patient starts
• State of marketing authorization and payer inclusion
• Diminishing trial and pipeline attention

Projected directionality (not a growth thesis)

• Near term (0–12 months): residual use, low incremental starts
• Mid term (12–36 months): continued displacement, residual inventory and tail reimbursement
• Longer term (36–60 months): near-zero new patient adoption in most commercial settings

What patent estate protects boceprevir and when do key exclusivities expire?

Critical note for commercial risk: Patent and exclusivity timelines matter less than guideline displacement for boceprevir’s commercial outlook. Still, they define generic and competitive entry mechanics for any remaining supply tail.

Quick answer: For older HCV DAAs like boceprevir, patents and exclusivities from the original approval era have largely run their course or are in late-stage post-approval wind-down. The market has already moved to newer products.

How does patent expiration affect residual boceprevir availability?

• When patents expire, generic entry can affect price and availability
• Even with generic entry, demand can remain low if prescribers have moved on

What generic entry risks existed for VICTRELIS and how would they change the forecast?

Quick answer: Generic entry risk generally accelerates pricing pressure, but the dominant determinant of boceprevir volume is clinical displacement, not IP status. Thus, entry would mostly compress margins on any residual volume rather than create demand.

Which entry pathways would have been relevant historically?

• ANDA-style small molecule generic routes for boceprevir
• Labeling and combination regimen considerations (boceprevir is not used as monotherapy)

How would competitive pricing affect legacy use?

• Lower cost could extend minimal use in constrained access settings
• In practice, modern regimens still displace use, so the incremental patient population is limited

What is the regulatory status of VICTRELIS in the US and how does that affect current market access?

Quick answer: VICTRELIS is not the current center of HCV regulatory expansion. Market access is primarily legacy-based in settings that still carry older DAA products.

FDA status implications for a declining product

• If uptake is minimal, FDA labeling status changes have limited revenue effect
• If remaining patients exist, access depends on supply continuity and payer coverage rather than new approvals

How does boceprevir compare with leading HCV DAAs on efficacy and tolerability that drive switching?

Quick answer: Boceprevir’s key competitive disadvantages are interferon dependence and tolerability burdens. Newer DAAs offer higher convenience, fewer adverse events, and broader coverage.

Comparison axes that drive payer and clinician switching

• Interferon-free regimens
• Treatment duration
• Genotype coverage
• Drug-drug interaction profile
• Overall tolerability and monitoring burden

Which companies and products have displaced boceprevir in formularies and guidelines?

Quick answer: The displacement is led by broad classes of modern DAAs and fixed-dose combination products. The practical consequence is that boceprevir is largely excluded from current first-line treatment recommendations.

What displacement looks like commercially

• Formularies prioritize newer regimens with simpler monitoring and better adherence
• Prior authorization barriers favor modern combinations
• Real-world prescribing shifts away from older interferon-containing options

What formulation, manufacturing, and combination regimen barriers limit re-growth for VICTRELIS?

Quick answer: Re-growth is limited by the fact that boceprevir is used in a specific combination with peginterferon alfa and ribavirin. Even if boceprevir remained available, the regimen context reduces re-initiation.

Regimen-level barriers

• Need for peginterferon administration and monitoring
• Cytopenia management burden
• Treatment pathway complexity relative to newer options

Manufacturing and supply

• Any remaining supply is oriented toward legacy demand, not expansion
• Supply continuity does not offset demand decline if clinicians have stopped initiating

Key takeaways

• VICTRELIS (boceprevir) is a legacy interferon-based HCV DAA whose clinical and commercial relevance has been overtaken by interferon-free, more convenient DAAs.
• Clinical trial activity has not evolved into a boceprevir-led growth track; the key endpoints and milestones belong to the earlier DAA-interferon era.
• Market projection is flat-to-declining over 3–5 years, driven by guideline and formulary displacement more than patent or regulatory mechanics.
• Any remaining exposure is residual legacy use; generic entry would mainly compress pricing on limited volume rather than revive demand.
• Commercial barriers are regimen-level (peginterferon and ribavirin reliance) and patient tolerability monitoring burdens relative to current standard-of-care DAAs.

FAQs

1. Why was boceprevir historically used only with peginterferon alfa and ribavirin?
2. What adverse events drove real-world discontinuation risk for boceprevir regimens?
3. How did response-guided treatment durations work in boceprevir trials?
4. Do any countries still rely on boceprevir-containing regimens for genotype 1 HCV?
5. What is the main driver of boceprevir’s market decline: patents, reimbursement, or guideline switching?

References

1. FDA. VICTRELIS (boceprevir) prescribing information. U.S. Food and Drug Administration.
2. European Medicines Agency (EMA). VICTRELIS (boceprevir) product information.
3. AASLD/IDSA. Practice Guidance for the management of hepatitis C (HCV) and updates reflecting interferon-free DAA standard of care. American Association for the Study of Liver Diseases / Infectious Diseases Society of America.